midazolam + lormetazepam

This entry refers to a retrospective cohort study (RetroLoveMi) conducted at Charité-Universitätsmedizin Berlin comparing the benzodiazepine sedatives midazolam and lormetazepam in critically ill, mechanically ventilated patients. Both agents are small molecule GABA-A receptor positive allosteric modulators used for ICU sedation. Midazolam is a short-acting benzodiazepine primarily metabolized via the cytochrome P450 (CYP3A4) pathway, which can lead to unpredictable drug accumulation and prolonged sedation in the context of critical illness or drug interactions. In contrast, lormetazepam undergoes direct Phase II metabolism via glucuronidation, which is independent of the cytochrome P450 system, potentially providing more stable pharmacokinetics in ICU patients. The study, led by investigators such as Claudia Spies, found that lormetazepam was associated with lighter sedation depth and lower ICU mortality compared to midazolam.

Brand names

DormicumVersedNoctamidErgocalmLoramet

Other names

midazolam vs. lormetazepam-Charite University, Berlin, Germany-critical illness